Participant flow16

How many started, completed or left each group, period by period.

1 to 16 of 16

Period	Milestone	Group	Participants
Overall Study	STARTED	Albendazole 400mg	38
Overall Study	STARTED	Albendazole/Ivermectin	57
Overall Study	STARTED	Albendazole 400mg x 3	23
Overall Study	STARTED	Albendazole/Ivermectin x 3	58
Overall Study	Safety Population	Albendazole 400mg	38
Overall Study	Safety Population	Albendazole/Ivermectin	56
Overall Study	Safety Population	Albendazole 400mg x 3	23
Overall Study	Safety Population	Albendazole/Ivermectin x 3	58
Overall Study	COMPLETED	Albendazole 400mg	24
Overall Study	COMPLETED	Albendazole/Ivermectin	35
Overall Study	COMPLETED	Albendazole 400mg x 3	18
Overall Study	COMPLETED	Albendazole/Ivermectin x 3	40
Overall Study	NOT COMPLETED	Albendazole 400mg	14
Overall Study	NOT COMPLETED	Albendazole/Ivermectin	22
Overall Study	NOT COMPLETED	Albendazole 400mg x 3	5
Overall Study	NOT COMPLETED	Albendazole/Ivermectin x 3	18

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04041453/flow